November 16th 2022
Rana R. McKay, MD, discusses the potential impact of triplet therapies in the treatment paradigm for metastatic renal cell carcinoma and identifies several other areas for further study.
November 10th 2022
Shared insight on the evolving treatment landscape of renal cell carcinoma and expectations for future evolution in the paradigm.
Before closing out there review of non–clear cell RCC management, expert oncologists highlight novel therapeutic strategies and ongoing clinical trials.
November 4th 2022
Rana R. McKay, MD, discusses the rationale for combining tivozanib with nivolumab in heavily pretreated patients with renal cell carcinoma.
November 3rd 2022
Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.
Comprehensive insight to the optimal selection and sequencing of therapy for advanced clear cell RCC in the second-line setting and beyond.
October 27th 2022
Centering their discussion on the second-line setting, expert oncologists review mainstay second-line therapies for advanced clear cell RCC.
Expert perspectives on key clinical trials studying first-line adjuvant therapy in patients with advanced clear cell renal cell carcinoma.
October 20th 2022
Focusing on novel first-line triplet therapy combinations, panelists consider which regimens may find a role in the management of advanced clear cell RCC.
An expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.
October 13th 2022
Before closing out their review of mainstay combination therapy in the first-line setting of advanced clear cell RCC, panelists reflect on available quality of life data.
Focused discussion on brain metastases or sarcomatoid disease in advanced clear cell RCC and the selection of first-line treatment regimens.
October 6th 2022
Shared insight on the importance of sites of metastases and how they may impact first-line treatment selection in advanced clear cell RCC.
Centering conversation on systemic therapy, panelists review trial data behind the first-line combination regimens for patients with advanced clear cell RCC.
September 29th 2022
Comprehensive insight to the role of nephrectomy over systemic therapy in patients who receive a diagnosis of advanced clear cell RCC.
Expert oncologists open their discussion on advanced clear cell RCC by identifying its prevalence and prognoses before moving into treatment considerations.
November 18th 2020
In this review, authors highlight multidisciplinary treatment for patients with advanced disease, and integrating systemic therapy options with surgery and radiation therapy.
August 13th 2020
Rana R. McKay, MD, discusses the role of age and gender in advanced renal cell carcinoma outcomes.
June 25th 2020
Rana R. McKay, MD, discusses the design of the phase 3 PDIGREE study in advanced renal cell carcinoma.
June 3rd 2020
Rana R. McKay, MD, discusses adapting treatment for patients with cancer during the coronavirus disease 2019 pandemic.